Article citationsMore>>

Stannah, J., Soni, N., Lam, J.K.S., Giguère, K., Mitchell, K.M., Kronfli, N., et al. (2023) Trends in HIV Testing, the Treatment Cascade, and HIV Incidence among Men Who Have Sex with Men in Africa: A Systematic Review and Meta-analysis. The Lancet HIV, 10, e528-e542.
https://doi.org/10.1016/s2352-3018(23)00111-x

has been cited by the following article:

• TITLE: No Dichotomy in Double Counting of CD4 + T Cell Values on PIMA™® and BD FACSPresto™® in Benin

  AUTHORS: Edmond Tchiakpe, Alain K. AÏSSI, Djibril Wade, Akadiri Yessoufou

  KEYWORDS: BD FACSCount™®, FACSPresto™®, PIMA™®, PLHIV-1, CD4 + T cell, Benin

  JOURNAL NAME: Open Journal of Immunology, Vol.15 No.2, June 27, 2025

  ABSTRACT: The survival of PLHIV-1 by the count of CD4 + T lymphocytes remains essential to predict the treatment of opportunistic infections. The aim of the study was to compare the performance of PIMA™® and FACSPresto™® to the conventional equipment of FACSCount™® through CD4 + T cell counting. CD4 + T lymphocytes were tested both on PIMA™® and BD FACSPresto™®. Values were compared to those obtained from FACSCount™®, using Passing Bablok, Bland-Altman and Pollock diagrams. PIMA™® and FACSPresto™® present a good correlation coefficient with the Passing Bablok diagram (y = −0.5982 + 0.9940x; ρc = 0.9969) and (y = 7.2913 + 0.9974x; ρc = 0.9972) respectively. Bland-Altman and Pollock plots show mean biases of 3.7 cells/μL (LOA ranging from −62.7 to 60.1) and 0.5 cells/μL (LOA ranging from −10.7 to 11.6) for PIMA™® and −1.5 cells/μL (LOA ranging from −45.7 to 42.7) and −1.9 cells/μL (LOA ranging from −23.4 to 19.6) for FACSPresto™®. Sensitivity and specificity of PIMA™® and FACSPresto™® vary respectively between 98 to 99% and 96 to 98% at threshold of 350 cells/μL and 98 to 100% at threshold of 500 cells/μL. Both technologies highlight their ability to be used as an alternative to the reference technique.